Nylon-3 polymers active against
A method and corresponding composition to inhibit outgrowth of C. difficile spores and/or to inhibit growth of C. difficile vegetative cells in a mammal in which an amount of a nylon-3 polymer or nylon-3 copolymer or a pharmaceutically suitable salt thereof is administered to the subject.
1. A method of inhibiting outgrowth of C. difficile spores and/or inhibiting growth of C. difficile vegetative cells comprising contacting the spores or cells with an amount of a nylon-3 polymer or nylon-3 copolymer or a pharmaceutically suitable salt thereof, wherein the amount is effective to inhibit outgrowth of the C. difficile spores and/or to inhibit growth of the C. difficile vegetative cells.
2. The method of claim 1 , wherein the nylon-3 polymer or copolymer comprises subunits selected from the group consisting of
wherein:
R 3 , R 4 , R 5 , and R 6 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1 -C 6 -alkyl, aryl, C 1 -C 6 -alklyaryl, amino, protected-amino, amino-C 1 -C 6 -alkyl, protected-amino-C 1 -C 6 -alkyl, guanidine, thioalkyl, alkylthioalkyl, amino-substituted alkylthioalkyl, or R 3 and R 4 combined define a cyclic substituent selected from the group consisting of C 4 -C 12 cycloalkyl, C 4 -C 12 cycloalkenyl, and five- to twelve-membered heterocyclic;
“n” is an integer from 0 to 8; and
“A” is selected from the group consisting of substituted or unsubstituted C 4 -C 12 cycloalkyl, C 4 -C 12 cycloalkenyl, and five- to twelve-membered heterocyclic.
3. The method of claim 1 , wherein the nylon-3 polymer or copolymer has an average chain length of at least 5 subunits.
4. The method of claim 1 , wherein the nylon-3 polymer or copolymer has an average chain length at of least 15 subunits.
5. The method of claim 1 , wherein the nylon-3 polymer or copolymer has an average chain length at of at least 20 subunits.
6. The method of claim 1 , wherein the nylon-3 polymer or copolymer has an average chain length at of between 5 and 120 subunits.
7. The method of claim 1 , wherein the nylon-3 polymer or copolymer is selected from the group consisting of:
wherein R is selected from the same group of substituents as R 3 through R 6 .
8. A method of inhibiting outgrowth of C. difficile spores and/or inhibiting growth of C. difficile vegetative cells in a mammal comprising administering to the mammal an amount of a nylon-3 polymer or nylon-3 copolymer or a pharmaceutically suitable salt thereof, wherein the amount is effective to inhibit outgrowth of the C. difficile spores and/or to inhibit growth of the C. difficile vegetative cells in the mammal.
9. The method of claim 8 , wherein the nylon-3 polymer or copolymer comprises subunits selected from the group consisting of
wherein:
R 3 , R 4 , R 5 , and R 6 are each independently selected from the group consisting of hydrogen, substituted or unsubstituted C 1 -C 6 -alkyl, aryl, C 1 -C 6 -alklyaryl, amino, protected-amino, amino-C 1 -C 6 -alkyl, protected-amino-C 1 -C 6 -alkyl, guanidine, thioalkyl, alkylthioalkyl, amino-substituted alkylthioalkyl, or R 3 and R 4 combined define a cyclic substituent selected from the group consisting of C 4 -C 12 cycloalkyl, C 4 -C 12 cycloalkenyl, and five- to twelve-membered heterocyclic;
“n” is an integer from 0 to 8; and
“A” is selected from the group consisting of substituted or unsubstituted C 4 -C 12 cycloalkyl, C 4 -C 12 cycloalkenyl, and five- to twelve-membered heterocyclic.
10. The method of claim 8 , wherein the nylon-3 polymer or copolymer has an average chain length at of at least 5 subunits.
11. The method of claim 8 , wherein the nylon-3 polymer or copolymer has an average chain length at of at least 15 subunits.
12. The method of claim 8 , wherein the nylon-3 polymer or copolymer has an average chain length at of at least 20 subunits.
13. The method of claim 8 , wherein the nylon-3 polymer or copolymer has an average chain length at of between 5 and 120 subunits.
14. The method of claim 8 , wherein the nylon-3 polymer or copolymer is selected from the group consisting of:
wherein R is selected from the same group of substituents as R 3 through R 6 .
15. The method of claim 8 , wherein the amount of the nylon-3 polymer or copolymer is administered enterally.
16. The method of claim 8 , wherein the amount of the nylon-3 polymer or copolymer is administered parenterally.